Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Metrics to compare | ELTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipELTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.5x | −4.3x | −0.5x | |
PEG Ratio | −0.14 | −0.04 | 0.00 | |
Price / Book | 132.5x | 6.4x | 2.6x | |
Price / LTM Sales | - | 10.3x | 3.2x | |
Upside (Analyst Target) | 49.2% | 188.3% | 45.7% | |
Fair Value Upside | Unlock | −21.7% | 4.8% | Unlock |